Trials / Unknown
UnknownNCT05186649
Left Atrial Appendage (LAA) Clot With Severe Mitral Stenosis
Left Atrial Appendage (LAA) Clot With Severe Mitral Stenosis, Responders and Non-responders With Anticoagulation
- Status
- Unknown
- Phase
- —
- Study type
- Observational
- Enrollment
- 52 (estimated)
- Sponsor
- University of Karachi · Academic / Other
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
Consecutive patients with severe mitral stenosis and clot in left atrial appendage (LAA) on transesophageal echocardiography fulfilling the inclusion criteria will be recruited for this study. An ACUSON 128-XP echocardiographic system equipped with omniplane and biplane transesophageal probes will be used for this study. TEE followed by CT Angiography will be performed according to the standard procedure after obtaining informed consent.
Detailed description
Consecutive patients with severe mitral stenosis and clot in left atrial appendage (LAA) on transesophageal echocardiography fulfilling the inclusion criteria will be recruited for this study. An ACUSON 128-XP echocardiographic system equipped with omniplane and biplane transesophageal probes will be used for this study. TEE followed by CT Angiography will be performed according to the standard procedure after obtaining informed consent. Demographic profile of the patients will be recorded like gender and age. And baseline TEE will be interpreted and parameters such as mean MVO (cm2), mean MPG (mmHg), and mean LA size (AP diameter, cm) will be recorded. LAA morphologies will be classified as per the operational definition. All the patients will be put on oral anticoagulation with Warfarin. The international normalized ratio (INR) will be maintained between 2.5 and 3.5. Patients will be prescribed with warfarin initial with 5 mg of daily dosage. Weekly INR monitoring will be performed via weekly calls to each and every patients and their INR level will be obtained. Warfarin daily dosage will be adjusted after every month based on target INR range. Repeat TEE will be performed after three (3) months in all the patients. And presence and absence of clot in different types of LAA will be recorded.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | WARFARIN | 5 mg of daily dosage |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2022-06-30
- Completion
- 2022-07-15
- First posted
- 2022-01-11
- Last updated
- 2022-01-11
Locations
1 site across 1 country: Pakistan
Source: ClinicalTrials.gov record NCT05186649. Inclusion in this directory is not an endorsement.